PFE - Pfizer Inc.
36.80 0.00 (0.00%)
After hours: 6:35PM EDT
| Previous Close | 36.63 |
| Open | 36.67 |
| Bid | 36.80 x 2400 |
| Ask | 37.00 x 500 |
| Day's Range | 36.60 - 36.89 |
| 52 Week Range | 31.67 - 39.43 |
| Volume | 24,080,246 |
| Avg. Volume | 24,894,629 |
| Market Cap | 218.908B |
| Beta | 0.95 |
| PE Ratio (TTM) | 10.46 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.36 (3.74%) |
| Ex-Dividend Date | 2018-02-01 |
| 1y Target Est | N/A |
- Motley Fool•5 hours ago
Don't Get Greedy With Novavax, Inc. Stock
Novavax's abysmal track record should be a huge red flag for potential shareholders.
- Market Realist•5 hours ago
Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected
Wall Street analysts expect an ~3.0% increase in Eli Lilly & Co.’s (LLY) 1Q18 revenues to $5.5 billion. Eli Lilly’s products are sold in more than 120 countries, and its international sales comprise ~45.0% of its total revenues. As a result, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenues during 1Q18.
- Market Realist•7 hours ago
Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.
- Zacks•7 hours ago
Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy
Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.
- Zacks•9 hours ago
Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?
Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.
- Market Realist•9 hours ago
Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.
- Reuters•10 hours ago
FDA declines to approve Pfizer biosimilar of Roche's cancer drug
Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information. Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision.
- Market Realist•10 hours ago
Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.
- Market Realist•11 hours ago
What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings
GlaxoSmithKline (GSK) is set to release its 1Q18 earnings on April 25, 2018. The below chart shows the company’s revenues and earnings per share (or EPS) since 1Q17 and analysts’ estimates for 1Q18. Analysts estimate the company will post EPS of 24.21 pence on revenues of 7.2 billion pounds in 1Q18.
- MarketWatch•11 hours ago
Pfizer says FDA failed to approve Herceptin biosimilar
Pfizer Inc. said early Monday that the Food and Drug Administration failed to approve its trastuzumab biosimilar, intended as a lower-cost version of Roche's cancer drug Herceptin. The FDA asked for more ...
- Moody's•yesterday
NMC Health plc -- Moody's assigns first-time Ba1 ratings to NMC Health; outlook stable
Moody's Investors Service, ("Moody's") has assigned a Ba1 corporate family rating (CFR) and Ba1-PD probability of default rating to NMC Health plc (NMC), the largest healthcare provider in the ...
- Motley Fool•yesterday
Better Buy: Gilead Sciences, Inc. (GILD) vs. Pfizer (PFE)
Which stock wins in a match-up between these huge drugmakers?
Market Realist•3 days agoAnalysts’ Ratings for Sarepta Therapeutics and Peers in April
How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.
Reuters•3 days agoP&G's vitamin boost could signal more to come
LONDON/CHICAGO (Reuters) - Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business demonstrates that major consumer companies remain hungry for health-related products. The fragmented nature of the sector and its appeal to younger consumers makes further M&A activity a likely prospect even after a spate of recent acquisitions. The U.S.-based maker of Tide detergent and Gillette razors announced its plan on Thursday to buy Merck brands such as Seven Seas vitamins.
- Zacks•3 days ago
J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.
- TheStreet.com•3 days ago
Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business
Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.
Reuters•4 days agoP&G's vitamin boost could signal more to come
LONDON/CHICAGO (Reuters) - Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business is the latest example of a major consumer company stocking up on health-related products. Just last month, cleaning product maker Clorox Co agreed to buy multivitamin company Nutranext for $700 million. The moves show how global consumer goods companies are looking to new, interesting areas to offset flagging growth in their core businesses.
- Zacks•4 days ago
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC
AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.
Market Realist•4 days agoVyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.
- Market Realist•5 days ago
How Analysts View Tetraphase Pharmaceuticals in April 2018
Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.
- Market Realist•5 days ago
A Look at the Financial Performance of Spark Therapeutics
Spark Therapeutics (ONCE) generated revenue of $12 million in 2017 compared to $20.1 million in 2016. Under this collaboration, Spark Therapeutics maintains the responsibility for developing SPK-FIX candidates through Phase 1 and 2 trials. In November 2017, this agreement was amended, and Spark received a $10 million up-front payment and was eligible to receive an additional $15 million.
Market Realist•5 days agoAnalysts’ Ratings for Spark Therapeutics and Its Peers in April 2018
Spark Therapeutics (ONCE) is a leader in the field of gene therapy. Spark Therapeutics’ pipeline of gene therapy product candidates targets the retina, liver, and the central nervous system. Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations, and ten have given it “buy” recommendations.
- Market Realist•5 days ago
Analysts’ Ratings for Achaogen and Peers in April 2018
Achaogen (AKAO), a late-stage biopharmaceutical company, develops and commercializes antibacterial treatments for MDR (multidrug-resistant) gram-negative infections. Its lead product candidate, plazomicin, targets serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, which was identified as a “nightmare bacteria” by the Centers for Disease Control and Prevention in 2013. Of the 12 analysts covering Achaogen in April 2018, five have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “sell.” The mean rating for the stock is 1.8, and its target price is $21.56.
- Reuters•6 days ago
Canada seeks U.S. help to solve EpiPen shortage
Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access supplies of Mylan N.V.'s EpiPen emergency allergy antidote amid a growing shortage that has spared the United States. EpiPens deliver a potentially lifesaving dose of the generic drug epinephrine via an automatic injector. Last week, Pfizer notified consumers in Canada and Britain that the device is in short supply due to manufacturing problems.
InvestorPlace•6 days ago7 Stocks on a Long-Term Uptrend
Let’s call a spade a spade. Turnaround stocks are fun. They’re even more fun when you’re able to say you bought them at — or at least near — their low because you understood the underlying story better than most other investors did.
